Key clinical point: Patients with stage III melanoma who have circulating tumor cells (CTCs) at baseline may benefit from adjuvant therapy.
Major finding: Compared with patients who lacked CTCs, patients with CTCs were three times as likely to have disease recurrence within 6 months (hazard ratio, 3.13; P = .018).
Study details: A prospective study of 243 patients with stage III melanoma.
Disclosures: The study was funded by the Kiefer family, Sheila Prenowitz, the Simon and Linda Eyles Foundation, the Sam and Janna Moore family, and the Wintermann Foundation. The investigators reported no conflicts of interest.
Lucci et al. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-2670.